Observational studySleep & breathing = Schlaf & Atmung2026
Long-term effects of sleeve gastrectomy on metabolic parameters and obstructive sleep apnea resolution: a prospective observational study.
Observational study in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSleeve gastrectomy (SG) has emerged as the most effective metabolic and bariatric surgical intervention for managing obesity-related complications. The objective of this study is to investigate the long-term effects of SG on cardiometabolic parameters and the resolution of obstructive sleep apnea (OSA) five-year post-surgery.
methodsThis prospective cohort study conducted between (2018–2023) at our institution and included patients aged 18 to 60 years who underwent SG. We compared anthropometric, glycemic, blood pressure (BP), lipid profile and sleep apnea parameters at baseline and 5 years after surgery.
resultsA total of 48 patients included in the study, 70% were female with mean age 35.6 years. Patients achieved significant body mass index reduction from 45.8 ± 8.1 kg/m2 at baseline to 30.5 ± 6.82 kg/m² at 5 years with a excess weight loss percentage of 69.14%. Both waist and neck circumferences significantly decreased (P = 0.00 for each). Cardiometabolic parameters including blood pressure (BP), fasting blood glucose, hemoglobin A1c (HbA1c), homeostatic model assessment for insulin resistance (HOMA-IR), triglyceride, and high-density lipoprotein (HDL) showed significant improvements (P = 0.000 for all). However, changes in total cholesterol and low-density lipoprotein (LDL) did not reach statistical significance. The STOP-BANG questionnaire score decreased from 4.3 at baseline to 1.2 at 5 years. Similarly, the Apnea-Hypopnea Index significantly decreased from 22 at baseline to 6 five years post-surgery. Remission rates were 64.3% for hypertension (HTN), 71.4% for type 2 diabetes(T2DM), 58.1% for dyslipidemia, and 80% for OSA. Approximately 31% of our cohort experienced weight regain; however, they still retained their cardiometabolic improvements and OSA benefits five years after SG.
conclusionThe current study confirms that SG has a significant long-term impact on both cardiometabolic health with partial or even complete resolution of OSA. Clinical trial registration: ISRCTN62397779.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.